<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01361048</url>
  </required_header>
  <id_info>
    <org_study_id>TV-01</org_study_id>
    <nct_id>NCT01361048</nct_id>
  </id_info>
  <brief_title>Neo-Penotran Forte Vaginal Suppository for Vaginal Trichomoniasis</brief_title>
  <official_title>Neo-Penotran Forte Vaginal Suppository for Vaginal Trichomoniasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Alabama at Birmingham</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Embil Pharmaceutical Co. Ltd</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Alabama at Birmingham</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators are trying a combination vaginal product of higher dose metronidazole
      combined with miconazole to see if it is effective in treating vaginal trichomonas.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2011</start_date>
  <completion_date type="Actual">January 2013</completion_date>
  <primary_completion_date type="Actual">August 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants Cured of Vaginal Trichmonas</measure>
    <time_frame>day 12-15</time_frame>
    <description>percentage of participants achieving microbiological cure of trichomonas</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tolerability of the Study Product as Measured by Participant Self-report</measure>
    <time_frame>day 12-15 day 30-35</time_frame>
    <description>Number of participants with any side effects</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Trichomonas Vaginitis</condition>
  <arm_group>
    <arm_group_label>oral metronidazole</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>control arm</description>
  </arm_group>
  <arm_group>
    <arm_group_label>neo penotran forte</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>neo penotran forte vaginal suppository twice a day for 7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>neo penotran forte once a day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>neo penotran forte vaginal suppository once a day for 7 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oral metronidazole</intervention_name>
    <description>2 gm oral once</description>
    <arm_group_label>oral metronidazole</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>neo penotran forte</intervention_name>
    <description>neo penotran forte intravaginal twice a day for 7 days</description>
    <arm_group_label>neo penotran forte</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>neo penotran forte once a day</intervention_name>
    <description>neo penotran forte intravaginally once a day for 7 days</description>
    <arm_group_label>neo penotran forte once a day</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  presence of trichomonas

        Exclusion Criteria:

          -  pregnant or nursing

          -  known immunodeficiency

          -  allergy to study drugs

          -  concurrent yeast infection

          -  history of seizures or peripheral neuropathy

          -  unwillingness to abstain from alcohol during treatment period and for 48 hrs after
             concurrent lithium

          -  anticoagulation therapy, and abuse

          -  patient expected to have menses within 8 days of enrollment
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Personal Health Clinic UAB</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 24, 2011</study_first_submitted>
  <study_first_submitted_qc>May 25, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 26, 2011</study_first_posted>
  <results_first_submitted>November 18, 2013</results_first_submitted>
  <results_first_submitted_qc>January 6, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 20, 2014</results_first_posted>
  <last_update_submitted>December 19, 2017</last_update_submitted>
  <last_update_submitted_qc>December 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">January 19, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Alabama at Birmingham</investigator_affiliation>
    <investigator_full_name>Jane Schwebke</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>trichomonas</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaginitis</mesh_term>
    <mesh_term>Trichomonas Infections</mesh_term>
    <mesh_term>Trichomonas Vaginitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metronidazole</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Oral Metronidazole</title>
          <description>control arm</description>
        </group>
        <group group_id="P2">
          <title>Neo Penotran Forte</title>
          <description>neo penotran forte vaginal suppository twice a day for 7 days</description>
        </group>
        <group group_id="P3">
          <title>Neo Penotran Forte Once a Day</title>
          <description>neo penotran forte vaginal suppository once a day for 7 days</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Oral Metronidazole</title>
          <description>control arm</description>
        </group>
        <group group_id="B2">
          <title>Neo Penotran Forte Twice a Day</title>
          <description>neo penotran forte vaginal suppository twice a day for 7 days</description>
        </group>
        <group group_id="B3">
          <title>Neo Penotran Forte Once a Day</title>
          <description>neo penotran forte vaginal suppository once a day for 7 days</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
            <count group_id="B2" value="10"/>
            <count group_id="B3" value="10"/>
            <count group_id="B4" value="40"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="40"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31.9" spread="11.8"/>
                    <measurement group_id="B2" value="31.5" spread="9.8"/>
                    <measurement group_id="B3" value="28.3" spread="6.7"/>
                    <measurement group_id="B4" value="30.5" spread="10.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="40"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Cured of Vaginal Trichmonas</title>
        <description>percentage of participants achieving microbiological cure of trichomonas</description>
        <time_frame>day 12-15</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Oral Metronidazole 2 gm Stat Dose</title>
            <description>control arm</description>
          </group>
          <group group_id="O2">
            <title>Neo Penotran Forte</title>
            <description>neo penotran forte vaginal suppository twice a day for 7 days</description>
          </group>
          <group group_id="O3">
            <title>Neo Penotran Forte Once a Day</title>
            <description>neo penotran forte vaginal suppository once a day for 7 days</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Cured of Vaginal Trichmonas</title>
          <description>percentage of participants achieving microbiological cure of trichomonas</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90"/>
                    <measurement group_id="O2" value="90"/>
                    <measurement group_id="O3" value="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tolerability of the Study Product as Measured by Participant Self-report</title>
        <description>Number of participants with any side effects</description>
        <time_frame>day 12-15 day 30-35</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Oral Metronidazole</title>
            <description>control arm
oral metronidazole: 2 gm oral once</description>
          </group>
          <group group_id="O2">
            <title>Neo Penotran Forte</title>
            <description>neo penotran forte vaginal suppository twice a day for 7 days
neo penotran forte: neo penotran forte intravaginal twice a day for 7 days</description>
          </group>
          <group group_id="O3">
            <title>Neo Penotran Forte Once a Day</title>
            <description>neo penotran forte vaginal suppository once a day for 7 days
neo penotran forte once a day: neo penotran forte intravaginally once a day for 7 days</description>
          </group>
        </group_list>
        <measure>
          <title>Tolerability of the Study Product as Measured by Participant Self-report</title>
          <description>Number of participants with any side effects</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Oral Metronidazole</title>
          <description>control arm</description>
        </group>
        <group group_id="E2">
          <title>Neo Penotran Forte</title>
          <description>neo penotran forte vaginal suppository twice a day for 7 days</description>
        </group>
        <group group_id="E3">
          <title>Neo Penotran Forte Once a Day</title>
          <description>neo penotran forte vaginal suppository once a day for 7 days</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDR</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>suicicdal ideation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 10.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>vaginal itch</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>pilot study</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Jane Schwebke</name_or_title>
      <organization>UAB</organization>
      <phone>205-975-5665</phone>
      <email>schwebke@uab.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

